Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- 3rd Batch of Sakigake Drugs to Be Announced Soon: MHLW Official
March 15, 2018
- MHLW Issues Safety Information with Special Feature on MID-NET Expected to Begin Full-Scale Operation on April 1
March 15, 2018
- PMDA’s Review Segment to Post Loss of around 500 Million Yen in FY2017; Ordinary Loss to Be Covered by Reserve Fund
March 14, 2018
- PMDA to Establish “Regulatory Science Center” in April to Deal with Advanced Science and Technology
March 14, 2018
- MHLW to Relax Regulatory Procedures to Prevent Discrepancies between Approved and Actual Manufacturing Practices
March 13, 2018
- Lexicon: G1/G2 Rule
March 9, 2018
- AMED Taking Applications for FY2018 CiCLE Grant Program, Will Make Final Selection by Early October
March 9, 2018
- Funding Disclosure Methods that Prohibit Printing Will Not Be Acceptable: MHLW Notifications on Clinical Research Law
March 9, 2018
- MHLW Proposes Working Group Discussions before Another Round of CEA Analyses for 7 Products: Chuikyo
March 8, 2018
- Kadcyla’s Premium Portion Cut by 90% on CEA, 1 Device Gets Upward Adjustment: Chuikyo
March 8, 2018
- Xofluza Subject to April Price Revision, but Will Maintain Full Price: MHLW Official
March 8, 2018
- Why Did Xarelto, Eliquis Lose PMP Eligibility?
March 7, 2018
- Xofluza to Join NHI Price List March 14 as Key Panel Gives Expedited OK
March 7, 2018
- 10 Billion Yen Could Be Saved If 80% Gx Use Achieved among Welfare Recipients: Govt
March 6, 2018
- New Authorized Generic Re-Pricing Rule Applied to Olmetec, Crestor AGs
March 6, 2018
- Rituxan Biosimilar Price Down 9.5% as Originator Hit by Re-Pricing
March 6, 2018
- Winners and Losers of New PMP Criteria: Januvia Earns 1st Premium while Xarelto, Humira Miss It
March 6, 2018
- Annual Savings from Use of Biosimilars Stands at Just 8.7 Billion Yen: MHLW
March 6, 2018
- Hemophilia A Treatment Hemlibra, Zoster Vaccine Shingrix Clear MHLW Panel
March 5, 2018
- One-Time Blockbusters to Be Re-Priced at 2.5-Times Gx Price Average; Mevalotin, Takepron among the List
March 5, 2018
ページ
Japan’s health and finance ministers agreed late last year to go ahead with an “off-year” drug price revision in FY2027,…
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…